IR
ALXN

Invictus RG’s Alexion Pharmaceuticals ALXN Stock Holding History

Invictus RG’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,680
Closed -$790K – 160
2018
Q3 		$790K Buy
+5,680
New +$713K 0.61% 31
2017
Q4 		– Sell
-1,442
Closed -$202K – 555
2017
Q3 		$202K Buy
+1,442
New +$196K 0.18% 228

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invictus RG's ALXN Position: Q4 2018 in Review

Invictus RG sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 5,680 shares — an estimated $790K sold.

Invictus RG first reported a position in ALXN in Q3 2017 and held it in 2 quarters. The position peaked at $790K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Invictus RG reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Invictus RG sold 5,680 Alexion Pharmaceuticals shares in Q4 2018, an estimated $790K.
  • Invictus RG first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Invictus RG's Alexion Pharmaceuticals position peaked at $790K in Q3 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Invictus RG's 13F filing for Q4 2018, filed 13 Feb 2019.